Everything below concerns synthetic peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-06. Numbers and descriptions here follow the published literature rather than marketing material.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
=== Acidity === Carboxylic acids are Brønsted–Lowry acids because they are proton (H+) donors. They are the most common type of organic acid. Carboxylic acids are typically weak acids, meaning that they only partially dissociate into [H3O]+ cations and R−CO−2 anions in neutral aqueous solution. For example, at room temperature, in a 1-molar solution of acetic acid, only 0.001% of the acid are dissociated (i.e. 10−5 moles out of 1 mol). Electron-withdrawing substituents such as trifluoromethyl (−CF3) give stronger acids (the pKa of acetic acid is 4.76 whereas trifluoroacetic acid, with a trifluoromethyl substituent, has a pKa of 0.23). Electron-donating substituents give weaker acids (the pKa of formic acid is 3.75 whereas acetic acid, with a methyl substituent, has a pKa of 4.76)
Task Force 1-41 Infantry was a US Army heavy battalion task force from the 2nd Armored Division (Forward). 2nd Armored Division (Forward) included the 1st Battalion, 41st Infantry Regiment, the 2nd and 3rd Battalions, 66th Armor Regiment, and the 4th Battalion, 3rd Field Artillery Regiment. Task Force 1–41 was the first coalition force to breach the Saudi Arabian border on 15 February 1991, and to conduct ground combat operations in Iraq against the enemy on 17 February 1991. Shortly after arrival in theatre "..the battalion received, for planning, a brigade cross-boundary counter-reconnaissance mission." 1–41 Infantry was assisted by the 1st Squadron, 4th Armored Cavalry Regiment. This joint effort would become known as Task Force Iron. Counter-reconnaissance generally includes destroying or repelling the enemy's reconnaissance elements and denying their commander any observation of friendly forces. On 15 February 1991 4th Battalion of the 3rd Field Artillery Regiment fired on a trailer and a few trucks in the Iraqi sector observing American forces. On 16 February 1991 several groups of Iraqi vehicles appeared to be performing reconnaissance on the Task Force and were driven away by fire from 4–3 FA. Another enemy platoon, including six vehicles, was reported as being to the northeast of the Task Force. They were engaged with artillery fire from 4–3 FA. Later that evening another group of Iraqi vehicles was spotted moving towards the center of the Task Force. They appeared to be Iraqi Soviet-made BTRs and tanks.
CBN was the first cannabinoid to be isolated from cannabis extract in the late 1800s. Specifically, it was discovered by Barlow Wood, Newton Spivey, and Easterfield in 1896. In the early 1930s, CBN's structure was identified by Cahn, marking the first development of a cannabis extract. Its structure and chemical synthesis were achieved by 1940, followed by some of the first preclinical research studies to determine the effects of individual cannabis-derived compounds in vivo.
Sources: en.wikipedia.org
=== Social pressures === Social pressure is one of the factors that leads to doping in sport. The media and society work together to construct a view of what masculinity and femininity should look like. Adolescent athletes are constantly influenced by what they see on the media, and some go to extreme measures to achieve the ideal image since society channels Judith Butler's definition of gender as a performative act. Examples of social pressures were given in a study done on an online bodybuilding community where bodybuilders doped because they felt like it was a rite of passage to be accepted into the community, and to feel validated. Both men and women are being materialized in the context of doping in sport; in an interview involving 140 men, it was concluded that "bodily practices are essential for masculine identity," and it was determined that the media highly publicizes female athletes who were strong, and thin. This leads to the issue of the consumption of performance enhancement drugs to achieve muscular or thin figures, and the assumption that the opponents are also taking performance-enhancing drugs, deeming it as an acceptable behavior to conform to. In addition, society's embracement of the "winning is everything" spirit leads many athletes to participate in doping, hoping that they will not be caught.
He concluded his speech by saying that "great rejuvenation of the Chinese nation and making America great again can go hand in hand" and that "Let us meet the people's expectations and show our historical initiative, let us keep advancing the cause of friendship between our two peoples and work together to build a better world".
Na2B4O7 + 4 H2O2 + 2 NaOH → 2 Na2B2O4(OH)4 + H2O Sodium percarbonate, which is an adduct of sodium carbonate and hydrogen peroxide, is the active ingredient in such laundry products as OxiClean and Tide laundry detergent. When dissolved in water, it releases hydrogen peroxide and sodium carbonate. By themselves these bleaching agents are only effective at wash temperatures of 60 °C (140 °F) or above and so, often are used in conjunction with bleach activators, which facilitate cleaning at lower temperatures. Hydrogen peroxide has also been used as a flour bleaching agent and a tooth and bone whitening agent.
Sources: en.wikipedia.org
== Further reading == Attenborough, David (1957). Zoo Quest for a Dragon. London: Lutterworth Press. Auffenberg, Walter (1981). The Behavioral Ecology of the Komodo Monitor. Gainesville: University Presses of Florida. ISBN 978-0-8130-0621-5. Burden, W. Douglas (1927). Dragon Lizards of Komodo: An Expedition to the Lost World of the Dutch East Indies. New York, London: G.P. Putnum's Sons. Eberhard, Jo; King, Dennis; Green, Brian; Knight, Frank; Keith Newgrain (1999). Monitors: The Biology of Varanid Lizards. Malabar, Fla: Krieger Publishing Company. ISBN 978-1-57524-112-8. Lutz, Richard L; Lutz, Judy Marie (1997). Komodo: The Living Dragon. Salem, Or: DiMI Press. ISBN 978-0-931625-27-5. Westwood, Brett (28 August 2018). "Natural Histories: Komodo Dragon" (Audio (28 minutes)). BBC Radio. Retrieved 21 April 2023.
== Shopping bags == Commercial thermal shopping bags, to carry temperature-sensitive purchases home without breaking the cold chain, were first introduced by grocery and other shops in Europe in the mid-1980s. A thermal bag to keep pizzas being delivered hot was invented by Ingrid Kosar in 1983, and is commonly used now. A cool box is very similar in concept, but typically larger and in the form of a rigid box.
Cryobiology is the branch of biology that studies the effects of low temperatures on living things within Earth's cryosphere or in science. The word cryobiology is derived from the Greek words κρῧος [kryos], "cold", βίος [bios], "life", and λόγος [logos], "word". In practice, cryobiology is the study of biological material or systems at temperatures below normal. Materials or systems studied may include proteins, cells, tissues, organs, or whole organisms. Temperatures may range from moderately hypothermic conditions to cryogenic temperatures.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.